Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 6, 1999, Pages 315-320

  Fujiwara, Masatoshi ^a,b,g   Kodama, Eiichi N ^b   Okamoto, Masayuki ^a   Tokuhisa, Kenji ^a   Ide, Teruhiko ^c   Hanasaki, Yasuaki ^c   Katsuura, Kimio ^c   Takayama, Hiromitsu ^d   Aimi, Norio ^d   Mitsuya, Hiroaki ^e   Shigeta, Shiro ^b   Konno, Kenji ^a   Yokota, Tomoyuki ^a   Baba, Masanori ^f  

^a Rational Drug Design Laboratories   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c Tokyo Research Laboratories   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e NATIONAL CANCER INSTITUTE   (United States)

^f KAGOSHIMA UNIVERSITY   (Japan)

^g GLAXOSMITHKLINE   (United States)

Author keywords

NNRTI; Resistance; Thiadiazole

Indexed keywords

RD 4 2217; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS MUTANT;

EID: 0032757544     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000602     Document Type: Article

References (27)

1. Ahgren C, Backro K, Bell FW, Cantrell AS, Clemens M, Colacino JM, Deeter JB, Engelhardt JA, Hogberg M, Jaskunas SR, Johansson NG, Jordan CL, Kasher JS, Kinnick MD, Lind P, Lopez C, Morin JM Jr, Muesing MA, Noreen R, Oberg B, Paget CJ, Palkowitz JA, Parrish CA, Pranc P, Rippy MK, Rydergard C, Sahlberg C, Swanson S, Ternansky RJ, Unge T, Vasileff RT, Vrang L, West SJ, Zhang H & Zhou X-X (1995) The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 39:1329-1335.
2. Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D, Nakashima H, Perno C-F, Walker RT & Miyasaka T (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochemical Biophysical Research Communications 165:1375-1381.
3. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezu K, Nakashima H, Mori S, Shigeta S, Walker RT & Miyasaka T (1991) Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA 88:2356-2360.
4. Baba M, Shigeta S, Yuasa S, Takashima H, Sekiya K, Ubasawa M, Tanaka H, Miyasaka T, Walker RT & De Clercq E (1994) Preclinical eveluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrobial Agents and Chemotherapy 38:688-692.
5. Davey RT Jr, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL & Lane HC (1996) Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents and Chemotherapy 40:1657-1664.
6. Demeter LM, Meehan PM, Morse G, Geronedelis P, Dexter A, Berrious L, Cox S, Freimuth W & Reichman RC (1997) HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 14:136-144.
7. Fujiwara M, Ijichi K, Hanasaki H, Ide T, Katsuura K, Takayama H, Aimi N, Shigeta S, Konno K, Yokota T & Baba M (1997) Thiadiazole derivatives: Highly potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replications in vitro. Microbiology and Immunology 41:301-308.
8. Fujiwara T, Sato A, El-Farrash M, Miki S, Abe K, Isaka Y, Kodama M, Wu Y, Chen LB, Harada H, Sugimoto H, Hatanaka M, Hinuma Y (1998) S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 42:1340-1345.
9. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Hupe DJ, Emini EA & Stern AM (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences, USA 88:6863-6867.
10. Herzberg IM & DeLuca HF (1995) Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. BioTechniques 19:178-182.
11. Ijichi K, Fujiwara M, Hanasaki H, Watanabe H, Katsuura K, Takayama H, Shirakawa S, Sakai S, Shigeta S, Konno K, Yokota T & Baba M (1995) Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-yl N,N-dialkylcarbamatc derivatives. Antimicrobial Agents and Chemotherapy 39:2337-2340.
12. Ijichi K, Fujiwara M, Hanasaki H, Katsuura K, Shigeta S, Konno K, Yokota T & Baba M (1996) Inhibitory effect of 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-yl-N-methyl,N-ethylcarbamate on replication of human immunodeficiency virus type 1 and the mechanism of action. Biochemistry and Molecular Biology International 39:41-52.
13. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA & The Syndey Primary HIV Infection Study Group (1997) Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Journal of Infectious Diseases 175:1502-1506
14. Kimpton J & Emerman M (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. Journal of Virology 66:2232-2239.
15. Maeda Y, Venzon DJ & Mitsuya H (1998) Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. Journal of Infectious Diseases 177:1207-1213.
16. Miller V, Béthune M-P, Kober A, Stürmer M, Hertogs K, Pauwels R, Stoffels P & Staszewski S (1998) Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrobial Agents and Chemotherapy 42:3123-3129
17. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shin C-K, Eckner K, Hattox S, Adams J, Rosehthal AS, Faanes R, Eckner RJ, Koup RA & Sullivan JL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
18. Miyoshi I, Taguchi H, Kubonishi H, Yoshimoto S, Ohtsuki Y, Shiraishi Y & Akagi T (1982) Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monograph 28:219-228.
19. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 20:309-321.
20. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, De Clercq E & Janssen PAJ (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
21. Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, De Vreese K, Woestenborghs R, Vandamme A-M, Janssen CGM, Anne J, Cauwenbergh G, Desmyter J, Heykants J, Janssen MAC, De Clercq E & Janssen PAJ (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA 90:1711-1715.
22. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, Shih C-K, Myers M & Griffin J (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology 68:1660-1666.
23. Romero DL, Busso M, Tan C-K, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L & Tarpley WG (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA 88:8806-8810.
24. Schinazi RF, Larder BA & Mellors JW (1996) Mutations in retroviral genes associated with drug resistance. International Antiviral News 4:95-107.
25. Spence RA, Kati WM, Anderson KS & Johnson KA (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Science 267:988-993.
26. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PAJ & Arnold E (1994) Locations of anti-AIDS drug binding sited and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. Journal of Molecular Biology 243:369-387.
27. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, Pettibone DJ, O'Brien JA, Ball RG, Balani SK, Lin JH, Chen I, Schleif WA, Sardana W, Long WJ, Byrnes VW & Emini EA (1995) L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 39:2602-2605.